Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (avastin). ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2013 / 10 ...

Bevacizumab improves outcome for most recurrent glioblastoma patients, ... Although underlying mechanisms of action are unclear, ...

Bevacizumab is a monoclonal antibody that selectively binds to VEGF and shows promising clinical efficacy when used in combination regimens for the treatment of melanoma. 17,21,22 In the MM subgroup ...

Compared with the control arm, treatment with carboplatin and paclitaxel plus bevacizumab (15 mg/kg) resulted in a higher response rate (31.5% v 18.8%), longer median time to progression (7.4 v 4.2 ...